Ananda Developments Past Earnings Performance
Past criteria checks 0/6
Ananda Developments's earnings have been declining at an average annual rate of -54%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually.
Key information
-54.0%
Earnings growth rate
-16.1%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | n/a |
Return on equity | -1,750.6% |
Net Margin | n/a |
Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Ananda Developments makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 0 | -6 | 2 | 0 |
31 Oct 23 | 0 | -4 | 2 | 0 |
31 Jul 23 | 0 | -2 | 1 | 0 |
30 Apr 23 | 0 | -1 | 1 | 0 |
31 Jan 23 | 0 | -1 | 1 | 0 |
31 Oct 22 | 0 | -1 | 1 | 0 |
31 Jul 22 | 0 | -1 | 1 | 0 |
30 Apr 22 | 0 | -1 | 1 | 0 |
31 Jan 22 | 0 | -1 | 1 | 0 |
31 Oct 21 | 0 | -1 | 1 | 0 |
31 Jul 21 | 0 | -1 | 1 | 0 |
30 Apr 21 | 0 | -1 | 1 | 0 |
31 Jan 21 | 0 | 0 | 0 | 0 |
31 Oct 20 | 0 | 0 | 0 | 0 |
31 Jul 20 | 0 | 0 | 0 | 0 |
30 Apr 20 | 0 | 0 | 0 | 0 |
31 Jan 20 | 0 | 0 | 0 | 0 |
31 Oct 19 | 0 | 0 | 0 | 0 |
31 Jul 19 | 0 | -1 | 1 | 0 |
30 Apr 19 | 0 | 0 | 0 | 0 |
Quality Earnings: 1FX is currently unprofitable.
Growing Profit Margin: 1FX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1FX is unprofitable, and losses have increased over the past 5 years at a rate of 54% per year.
Accelerating Growth: Unable to compare 1FX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1FX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 1FX has a negative Return on Equity (-1750.65%), as it is currently unprofitable.